Abstract
Exploring HER-096: A novel approach to Parkinson’s Disease Parkinson’s disease, a progressive neurodegenerative disorder, poses significant challenges for both patients and researchers. In a recent interview with Henri Huttunen from Herantis Pharma Plc, we delved into the intricacies of their potential novel disease-modifying therapy, HER-096. The discussion covered various aspects, from the mechanism of action to the potential impact on public health. HER-096, developed from the neurotrophic factor CDNF, represents a groundbreaking approach to Parkinson’s disease. By targeting the unfolded protein response and brain inflammation that are triggered by alpha-synuclein aggregation, HER-096 aims to disrupt a vicious cycle in disease progression.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
